Gordi Toufigh, Tan Lai Hock, Hong Catherine, Hopkins Nancy J, Francom Steven F, Slatter J Greg, Antal Edward J
Pharmacia, 301 Henrietta Street, Kalamazoo, MI 49001.
J Clin Pharmacol. 2003 Oct;43(10):1161-7. doi: 10.1177/0091270003257455.
In vitro metabolism experiments have suggested a possible role for endogenous reactive oxygen species (ROS) in the in vivo clearance of linezolid, a synthetic antibiotic of the oxazolidinone class. This observation has resulted in the hypothesis that dietary antioxidant supplements might disturb the balance of ROS in vivo and thereby lower the clearance of linezolid. The purpose of this open-label, two-group parallel design study was to investigate whether continuous intake of widely used vitamin C or vitamin E will affect the pharmacokinetics of linezolid. A total of 28 healthy volunteers (27 male and 1 female), including 22 of Chinese origin, were administered a single oral dose of 600 mg linezolid on days 1 and 8. Half of the subjects received daily oral doses of 1000 mg vitamin C on days 2 through 9, whereas the other half were administered daily oral doses of 800 IU vitamin E during the same time period. Serial blood samples for assessment of the pharmacokinetic parameters of linezolid and its two inactive metabolites were collected on days 1 and 8, whereas vitamin concentrations were measured prior to and after the vitamin intake on these days. Urine was collected on days 1 and 8 to assess the fraction of dose excreted as linezolid and its major metabolites. All linezolid samples were analyzed according to validated HPLC/MS/MS methods. Linezolid was well tolerated in both groups with no reported clinically significant adverse events. No significant changes were found between the day 1 and day 8 AUC0- infinity and Cmax values of linezolid in either the vitamin C treatment group (p = 0.55 and p = 0.64, respectively) or the vitamin E treatment group (p = 0.06 and p = 0.49, respectively). Assessment of other pharmacokinetic parameters did not imply any change across the study groups. In conclusion, linezolid pharmacokinetics are not affected by concomitant administration with vitamins C and E. Therefore, no dose adjustment is necessary in patients taking vitamin C or vitamin E. These no-effect drug interaction data are in accord with current literature indicating that antioxidant vitamins have only subtle effects on overall ROS balance in vivo.
体外代谢实验表明,内源性活性氧(ROS)可能在恶唑烷酮类合成抗生素利奈唑胺的体内清除过程中发挥作用。这一观察结果引发了一个假设,即膳食抗氧化剂补充剂可能会扰乱体内ROS的平衡,从而降低利奈唑胺的清除率。这项开放标签、两组平行设计研究的目的是调查持续摄入广泛使用的维生素C或维生素E是否会影响利奈唑胺的药代动力学。共有28名健康志愿者(27名男性和1名女性),其中包括22名中国受试者,在第1天和第8天接受了单次口服600 mg利奈唑胺的剂量。一半受试者在第2天至第9天每天口服1000 mg维生素C,而另一半受试者在同一时间段内每天口服800 IU维生素E。在第1天和第8天采集系列血样,以评估利奈唑胺及其两种无活性代谢物的药代动力学参数,同时在这两天维生素摄入前后测量维生素浓度。在第1天和第8天收集尿液,以评估以利奈唑胺及其主要代谢物形式排泄的剂量分数。所有利奈唑胺样品均根据经过验证的HPLC/MS/MS方法进行分析。两组中利奈唑胺的耐受性良好,未报告有临床显著不良事件。在维生素C治疗组(分别为p = 0.55和p = 0.64)或维生素E治疗组(分别为p = 0.06和p = 0.49)中,第1天和第8天利奈唑胺的AUC0-无穷大值和Cmax值均未发现显著变化。对其他药代动力学参数的评估未显示各研究组之间有任何变化。总之,利奈唑胺的药代动力学不受与维生素C和E同时给药的影响。因此,服用维生素C或维生素E的患者无需调整剂量。这些无效应的药物相互作用数据与当前文献一致,表明抗氧化维生素对体内整体ROS平衡只有微妙影响。